IShares Pharmaceuticals Etf Forward View
| IHE Etf | USD 86.68 0.35 0.41% |
IShares Etf outlook is based on your current time horizon. Investors can use this forecasting interface to forecast IShares Pharmaceuticals stock prices and determine the direction of iShares Pharmaceuticals ETF's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of IShares Pharmaceuticals' historical fundamentals, such as revenue growth or operating cash flow patterns.
The relative strength momentum indicator of IShares Pharmaceuticals' etf price is about 60. This usually indicates that the etf is rather overbought by investors at the present time. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling IShares, making its price go up or down. Momentum 60
Buy Extended
Oversold | Overbought |
Using IShares Pharmaceuticals hype-based prediction, you can estimate the value of iShares Pharmaceuticals ETF from the perspective of IShares Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards IShares Pharmaceuticals using IShares Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards IShares using crowd psychology based on the activity and movement of IShares Pharmaceuticals' stock price.
IShares Pharmaceuticals Implied Volatility | 0.29 |
IShares Pharmaceuticals' implied volatility exposes the market's sentiment of iShares Pharmaceuticals ETF stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if IShares Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that IShares Pharmaceuticals stock will not fluctuate a lot when IShares Pharmaceuticals' options are near their expiration.
The Naive Prediction forecasted value of iShares Pharmaceuticals ETF on the next trading day is expected to be 86.51 with a mean absolute deviation of 0.73 and the sum of the absolute errors of 44.49. IShares Pharmaceuticals after-hype prediction price | USD 86.68 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as etf price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of IShares Pharmaceuticals to cross-verify your projections. Prediction based on Rule 16 of the current IShares contract
Based on the Rule 16, the options market is currently suggesting that iShares Pharmaceuticals ETF will have an average daily up or down price movement of about 0.0181% per day over the life of the 2026-04-17 option contract. With IShares Pharmaceuticals trading at USD 86.68, that is roughly USD 0.0157 . If you think that the market is fully incorporating IShares Pharmaceuticals' daily price movement you should consider acquiring iShares Pharmaceuticals ETF options at the current volatility level of 0.29%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-04-17 IShares Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast IShares Pharmaceuticals' spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in IShares Pharmaceuticals' options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for IShares Pharmaceuticals stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current IShares Pharmaceuticals' open interest, investors have to compare it to IShares Pharmaceuticals' spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of IShares Pharmaceuticals is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in IShares. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
IShares Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine IShares price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for IShares using various technical indicators. When you analyze IShares charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
IShares Pharmaceuticals Naive Prediction Price Forecast For the 1st of February
Given 90 days horizon, the Naive Prediction forecasted value of iShares Pharmaceuticals ETF on the next trading day is expected to be 86.51 with a mean absolute deviation of 0.73, mean absolute percentage error of 0.89, and the sum of the absolute errors of 44.49.Please note that although there have been many attempts to predict IShares Etf prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that IShares Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
IShares Pharmaceuticals Etf Forecast Pattern
| Backtest IShares Pharmaceuticals | IShares Pharmaceuticals Price Prediction | Buy or Sell Advice |
IShares Pharmaceuticals Forecasted Value
In the context of forecasting IShares Pharmaceuticals' Etf value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. IShares Pharmaceuticals' downside and upside margins for the forecasting period are 85.53 and 87.50, respectively. We have considered IShares Pharmaceuticals' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of IShares Pharmaceuticals etf data series using in forecasting. Note that when a statistical model is used to represent IShares Pharmaceuticals etf, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 117.9983 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.7294 |
| MAPE | Mean absolute percentage error | 0.0088 |
| SAE | Sum of the absolute errors | 44.4931 |
Predictive Modules for IShares Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as iShares Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the etf market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the etf market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.IShares Pharmaceuticals After-Hype Price Density Analysis
As far as predicting the price of IShares Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in IShares Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Etf prices, such as prices of IShares Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
IShares Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting IShares Pharmaceuticals' etf value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on IShares Pharmaceuticals' historical news coverage. IShares Pharmaceuticals' after-hype downside and upside margins for the prediction period are 85.69 and 87.67, respectively. We have considered IShares Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
IShares Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of iShares Pharmaceuticals is based on 3 months time horizon.
IShares Pharmaceuticals Etf Price Outlook Analysis
Have you ever been surprised when a price of a ETF such as IShares Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading IShares Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Etf price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with IShares Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.22 | 0.98 | 0.02 | 0.10 | 5 Events / Month | 5 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
86.68 | 86.68 | 0.00 |
|
IShares Pharmaceuticals Hype Timeline
On the 31st of January iShares Pharmaceuticals is traded for 86.68. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of 0.1. IShares is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 0.22%. %. The volatility of related hype on IShares Pharmaceuticals is about 219.24%, with the expected price after the next announcement by competition of 86.78. The company has price-to-book (P/B) ratio of 1.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. Considering the 90-day investment horizon the next forecasted press release will be in about 5 days. Check out Historical Fundamental Analysis of IShares Pharmaceuticals to cross-verify your projections.IShares Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to IShares Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict IShares Pharmaceuticals' future price movements. Getting to know how IShares Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how IShares Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| IYM | iShares Basic Materials | 3.46 | 5 per month | 0.92 | 0.16 | 2.02 | (1.55) | 4.11 | |
| IYZ | iShares Telecommunications ETF | (0.12) | 3 per month | 0.89 | 0.1 | 1.64 | (1.55) | 4.40 | |
| REM | iShares Mortgage Real | 0.05 | 12 per month | 0.98 | 0.04 | 1.76 | (1.20) | 4.86 | |
| IGE | iShares North American | (0.22) | 11 per month | 0.84 | 0.21 | 1.58 | (1.56) | 3.89 | |
| DWM | WisdomTree International Equity | 0.23 | 1 per month | 0.55 | 0.09 | 1.11 | (1.14) | 3.11 | |
| PPH | VanEck Pharmaceutical ETF | 0.38 | 7 per month | 0.52 | 0.19 | 1.87 | (1.20) | 4.58 | |
| BKMC | BNY Mellon Mid | 0.67 | 4 per month | 0.82 | 0.03 | 1.61 | (1.33) | 3.69 | |
| INDY | iShares India 50 | 0.16 | 9 per month | 0.00 | (0.19) | 0.89 | (1.00) | 3.53 | |
| WCMI | First Trust Exchange Traded | 0.08 | 3 per month | 0.80 | 0.05 | 1.60 | (1.61) | 3.79 | |
| KSA | iShares MSCI Saudi | (0.22) | 3 per month | 0.00 | (0.05) | 1.54 | (1.57) | 4.78 |
Other Forecasting Options for IShares Pharmaceuticals
For every potential investor in IShares, whether a beginner or expert, IShares Pharmaceuticals' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. IShares Etf price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in IShares. Basic forecasting techniques help filter out the noise by identifying IShares Pharmaceuticals' price trends.IShares Pharmaceuticals Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with IShares Pharmaceuticals etf to make a market-neutral strategy. Peer analysis of IShares Pharmaceuticals could also be used in its relative valuation, which is a method of valuing IShares Pharmaceuticals by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
IShares Pharmaceuticals Market Strength Events
Market strength indicators help investors to evaluate how IShares Pharmaceuticals etf reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading IShares Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying IShares Pharmaceuticals etf market strength indicators, traders can identify iShares Pharmaceuticals ETF entry and exit signals to maximize returns.
IShares Pharmaceuticals Risk Indicators
The analysis of IShares Pharmaceuticals' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in IShares Pharmaceuticals' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting ishares etf prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 0.8019 | |||
| Semi Deviation | 0.5309 | |||
| Standard Deviation | 0.9949 | |||
| Variance | 0.9897 | |||
| Downside Variance | 0.7519 | |||
| Semi Variance | 0.2819 | |||
| Expected Short fall | (0.86) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for IShares Pharmaceuticals
The number of cover stories for IShares Pharmaceuticals depends on current market conditions and IShares Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that IShares Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about IShares Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Check out Historical Fundamental Analysis of IShares Pharmaceuticals to cross-verify your projections. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
The market value of iShares Pharmaceuticals is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is IShares Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because IShares Pharmaceuticals' market value can be influenced by many factors that don't directly affect IShares Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, IShares Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.